{
    "paper_id": "a6591c53501345df71d9fb2732abd0665cbbcb7e",
    "metadata": {
        "title": "Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity 1 2 Corresponding author",
        "authors": [
            {
                "first": "Niko",
                "middle": [],
                "last": "Kohmer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Goethe University Frankfurt am Main",
                    "location": {
                        "settlement": "Frankfurt",
                        "country": "5 Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Sandra",
                "middle": [],
                "last": "Westhaus",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Goethe University Frankfurt am Main",
                    "location": {
                        "settlement": "Frankfurt",
                        "country": "5 Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Cornelia",
                "middle": [],
                "last": "R\u00fchl",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Goethe University Frankfurt am Main",
                    "location": {
                        "settlement": "Frankfurt",
                        "country": "5 Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Sandra",
                "middle": [],
                "last": "Ciesek",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Goethe University Frankfurt am Main",
                    "location": {
                        "settlement": "Frankfurt",
                        "country": "5 Germany"
                    }
                },
                "email": "sandra.ciesek@kgu.de"
            },
            {
                "first": "Holger",
                "middle": [
                    "F"
                ],
                "last": "Rabenau",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Goethe University Frankfurt am Main",
                    "location": {
                        "settlement": "Frankfurt",
                        "country": "5 Germany"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "As the current SARS-CoV-2 pandemic continues, serological assays are urgently needed for rapid 25 diagnosis, contact tracing and for epidemiological studies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "As the current SARS-CoV-2 pandemic continues, serological assays are urgently needed for rapid 25 diagnosis, contact tracing and for epidemiological studies. So far, there is little data on how 26 commercially available tests perform with real patient samples and if detected IgG antibodies 27 provide protective immunity. Focusing on IgG antibodies, we demonstrate the performance of two 28 ELISA assays (Euroimmun SARS-CoV-2 IgG & Vircell COVID-19 ELISA IgG) in comparison to one lateral 29 flow assay ((LFA) FaStep COVID-19 IgG/IgM Rapid Test Device) and two in-house developed assays 30 (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)). We tested follow 31 up serum/plasma samples of individuals PCR-diagnosed with COVID-19. Most of the SARS-CoV-2 32 samples were from individuals with moderate to severe clinical course, who required an in-patient 33 hospital stay. 34",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract 24"
        },
        {
            "text": "For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection 35 (days 5-9) and from 93.8 to 100% for the later period (days 10-18) after PCR-diagnosed with COVID-36 19. With exception of one sample, all positive tested samples in the analysed cohort, using the 37 commercially available assays examined (including the in-house developed IFA), demonstrated 38 neutralizing (protective) properties in the PRNT, indicating a potential protective immunity to SARS-39 there is an increasing demand in the detection of antibodies -especially of IgG antibodies. 53 Convalescent plasma may be used for therapeutic or prophylactic approaches as vaccines and other 54 drugs are under development (2). For all these purposes, sensitive and especially highly specific 55 antibody assays are needed. The spike (S) protein of SARS-CoV-2 has shown to be highly 56 immunogenic and is the main target for neutralizing antibodies (3). Currently there are many S 57 protein based commercially or in-house developed assays available, but there is limited data on how 58 these tests perform with clinical samples and if the detected IgG antibodies provide protective 59",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract 24"
        },
        {
            "text": "immunity. This study aims to provide a quick overview on some of these assays (two commercial 60 available ELISA, an LFA, an IFA and a PRNT, focusing on the detection and neutralization capacity of In terms of sensitivity, our data are consistent with previously published data. In a study from Liu et 154 al., using an rS-based ELISA assay, the group found SARS-CoV-2 IgG antibodies in less than 60% of the 155 samples from days 6-10 after disease onset. The sensitivity increased to >90% in samples from days [especially for potential protective IgG antibodies against the S protein (6)] using ELISA or lateral flow 164 assays is more convenient and practicable than using the hands on-and time-intensive IFA or PRNT, 165 which can only be performed by experienced personnel, and the PRNT, only in a BSL-3 laboratory. 166 ELISA based assays can be automated and used for larger sample sizes. Lateral flow assays can be 167 used by less experienced personnel in a point-of-care setting, generating results in short time. Some 168 samples, however, were only detected with the IFA and PRNT as gold standard. The titer needed for 169 potential protective immunity is not yet (officially) defined. In one study, it is reported, that a 170 individual cleared SARS-CoV-2 without developing antibodies up to 46 days after illness (7). The 171 mechanism of immunity, especially of protective immunity (if applicable) and how long it will last, 172 need to be further investigated. Besides humoral mediated immunity, there is evidence that T-cell 173 ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract 24"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "SARS-CoV-2 and 197 Coronavirus Disease 2019: What We Know So Far",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "A"
                    ],
                    "last": "Rabi",
                    "suffix": ""
                },
                {
                    "first": "Al",
                    "middle": [],
                    "last": "Zoubi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Kasasbeh",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Salameh",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Al-Nasser",
                    "middle": [],
                    "last": "Ad",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.3390/pathogens9030231"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Convalescent plasma transfusion for the treatment of COVID-19: Systematic review",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rajendran",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Narayanasamy",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rangarajan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rathinam",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Natarajan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ramachandran",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Med Virol",
            "volume": "201",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25961"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Characterization of spike glycoprotein of SARS-CoV-2 on virus 204 entry and its immune cross-reactivity with SARS-CoV",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Mi",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Mu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hu 203",
                    "suffix": ""
                },
                {
                    "first": "Jin",
                    "middle": [
                        "Q"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qian",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Commun",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41467-020-15562-9"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "207 Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against 208 SARS-CoV-2",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Kou",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ding",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Microbiol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1128/JCM.00461-20"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Virological assessment of hospitalized patients with COVID-2019. 212 Nature",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wendtner",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41586-020-2196-x"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Perspectives on therapeutic neutralizing antibodies against the Novel 214",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Long-term 216 Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Kong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Geng",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "X-M",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "P-H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "217",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25946"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "The trinity of COVID-19: immunity, 219 inflammation and intervention",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "Z"
                    ],
                    "last": "Tay",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Poh",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "R\u00e9nia",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Macary",
                    "suffix": ""
                },
                {
                    "first": "Lfp",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Immunol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41577-020-0311-8"
                ]
            }
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Severe Acute 223 Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 224 Patients",
            "authors": [
                {
                    "first": "Cbem",
                    "middle": [],
                    "last": "Reusken",
                    "suffix": ""
                },
                {
                    "first": "B-J",
                    "middle": [],
                    "last": "Bosch",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "Mpg",
                    "middle": [],
                    "last": "Koopmans",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Haagmans",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Emerging Infect Dis",
            "volume": "26",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.3201/eid2607.200841"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "61IgG antibodies in follow up serum or plasma samples of individuals with PCR-diagnosed infections 62 with SARS-CoV-2. To assess potential cross-reactivity, we examined defined follow-up samples of 63 individuals infected with endemic coronaviruses and other infectious diseases. immunofluorescence assay Vero cells (african green monkey, ATCC CCL-81(American Type 95Culture Collection, Manassas, Virginia, USA)) were infected with SARS-CoV-2 and harvested two days 96 post infection. Briefly, cells were trypsinized and washed once with PBS before transferred onto a 10-97 well diagnostic microscope slides. After drying, cells were fixated with 100% ethanol for 10 minutes.98 Patient samples were diluted in sample buffer (Euroimmun AG, L\u00fcbeck, Germany) in a dilution of 99 1:50 and 30 \u00b5l applied per well. The slides were incubated at 37\u00b0C for 1 hour and washed three times 100 with phosphate-buffered saline (PBS)-Tween (0.1%) for 5 minutes. 25 \u00b5l of goat-anti human 101 fluorescein-labeled IgG conjugate was used as secondary antibody. The slides then were incubated 102 for 30 minutes and washed three times with PBS-Tween for 5 minutes. The microscopic analysis was 103 performed by 200-fold magnification using a Leica DMLS fluorescence microscope (Leica 104 Mikrosysteme Vertrieb GmbH, Wetzlar Germany). 105 106 Plaque reduction neutralization test (PRNT) 107 To test for neutralizing capacity of SARS-CoV-2 specific antibodies, Caco-2 cells (human colon 108 carcinoma cells, ATCC DSMZ ACC-169 (American Type Culture Collection, Manassas, Virginia, USA)) 109 were seeded on a 96-well plate 3-5 days prior infection. 2-fold dilutions of the test sera Tissue culture infectious dosis 50) of reference virus (SARS-CoV-2 FFM1 isolate). FFM1 was 113 isolated from a patient at University Hospital Frankfurt who was tested positive for SARS-CoV-2 by 114 PCR. Virus-serum mixture was incubated for one hour at 37\u00b0C and transferred onto the cell monolayer. Virus related cytopathic effects (CPE) were determined microscopically 48 17), the Assure Tech Rapid Test a sensitivity of 62.5% (10/16) and the Euroimmun ELISA a 122 sensitivity of 58.8% (10/17). For the later period from days 10-18, the Euroimmun ELISA and Assure 123 Tech Rapid Test showed a sensitivity 93.8% (15/16), the Vircell ELISA, IFA and PRNT of 100% (16/16) -124 (TABLE 1). For selected samples (SARS-CoV samples from the 2003 outbreak excluded, TABLE S2), the 125 Euroimmun ELISA showed a specificity of 95.7%, generating a borderline result for the HCoV-OC43 126 sample, the Vircell ELISA of 95.2%, generating a positive result for HCoV-229E sample and the in-127 house developed IFA of 100% (an unspecific result for one EBV sample was excluded). Including the 128 three SARS-CoV samples from the 2003 outbreak, the Euroimmun ELISA showed a specificity of 129 96.2% (not generating any cross-reactive results for the SARS-CoV samples), the IFA of 86.4% and the 130 Vircell ELISA of 83.3% (both assays generating positive results for all three SARS-CoV samples). The 131 Assure Tech Rapid Test did not generate any false positive results for the tested samples. None of the 132 other tested samples cross-reacted in terms of generating borderline or false positive results. 133 TABLE 1 -Sensitivity and specificity of the examined SARS-CoV-2 IgG assays from days 5-9 and days 10-18. 134 Company Days after confirmed SARS-CoV-2 PCR",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "135 related to SARS-CoV-2; **one \"borderline\" result; *** one unspecific result was excluded-, not examined.The signal-to-cut-off (S/CO) ratios of the Euroimmun and Vircell ELISA and the corresponding PRNT 138 titers for the tested samples are shown in FIG 1. In samples 3, 10 and 11, none of the examined 139 assays (including the IFA and Assure Tech Rapid Test), detected SARS-CoV-2 antibodies. In sample 1, 140 only the Vircell ELISA, in sample 4 and 19 only the Vircell ELISA and PRNT (including the IFA) detected 141 antibodies. In samples 12 and 16, only the PRNT (and IFA) detected antibodies (in sample 16 with a 142 titer <1:10). With exception of sample 1, all with the ELISA positive tested samples were also positive 143 tested with the IFA. In the detection of antibodies, the IFA performed like the PRNT on all examined 144 samples. All with the commercially available assays positive tested samples (except of sample 1) 145 showed neutralizing properties in the PRNT (titer >1:20), indicating a potential protective immunity. Results of the for sensitivity tested samples in the ELISA assays and PRNT; (A) Euroimmun ELISA Signal/Cut-off 149 (S/CO) ratio of tested samples; (B) Vircell ELISA Signal/Cut-off (S/CO) ratio for tested samples; (C) PRNT Titer for",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": ". In a study from W\u00f6lfel et al., using an in-house developed IFA, the group found 157 seroconversion in all examined follow-up serum samples of COVID-19 patients by day 14 after onset 158 of symptoms. The samples were further analyzed via PRNT, all showed neutralization activity finding of our study is, that (with exception of sample 1) all detected SARS-CoV-2 IgG 161 antibodies in the analyzed cohort, using the commercially available assays examined, demonstrated 162 neutralizing (protective) properties in the PRNT. The screening for SARS-CoV-2 IgG antibodies 163",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "mediated immunity plays a role (8). Most of the SARS-CoV-2 samples analysed in this study were with other active infectious diseases (e.g. EBV or CMV) are a known phenomenon (9). The examined 179 assays in our study demonstrated a good specificity. Only the Vircell ELISA generated one positive 180 result for one HCoV-229E sample, whereas the Euroimmun ELISA generated only one borderline 181 result for the HCoV-OC43 sample and the IFA an unspecific signal in one EBV sample. For the Assure 182 Tech Rapid Test, no cross-reactions were observed, however, a larger sample size would be needed 183 to get a clearer picture. The cross-reactivity of the SARS-CoV samples from the outbreak of 2003 in 184 the Vircell ELISA and IFA are of less importance as the virus is known to be eradicated. Nonetheless, 185 as a false positive result might give a false sense of security, efforts should be made to further 186 improve the specificity of the available assays. All in our study examined assays are eligible for the 187 detection of SARS-CoV-2 IgG antibodies, indicating a potential protective immunity. Ideally, to get the 188 maximum sensitivity, testing should be performed in the later phase of infection (\u2265 10 days) after 189 PCR-confirmation or disease onset of COVID-19. The Vircell ELISA, IFA and PRNT demonstrated the 190 highest sensitivity throughout our study. At the moment, however, the PRNT is still the method of 191 choice for questions regarding potential SARS-CoV-2 immunity and should be performed",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "specificity tested follow-up samples of individuals with selected PCR-or serologically-confirmed infections",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "CoV-2. Regarding specificity, there was evidence that samples of endemic coronavirus (HCoV-OC43, 40 HCoV-229E) and Epstein Barr virus (EBV) infected individuals cross-reacted in the ELISA assays and 41 IFA, in one case generating a false positive result (may giving a false sense of security). This need to 42 SARS-CoV-2 is a new Coronavirus, belonging to the group of betacoronaviruses, which emerged in 46 December 2019 in Wuhan, China. It is the causative agent of an acute respiratory disease known as 47 coronavirus disease 2019 (COVID-19). The spectrum of clinical signs can be very broad and 48 asymptomatic infections are reported. The virus has rapidly spread globally. On 11 March 2020 the 49 World Health Organization (WHO) declared COVID-19 as a pandemic. Nucleic acid amplification 50 testing (NAT) is the method of choice in the early phase of infection (1). However, to acquire 51knowledge about the seroprevalence of SARS-CoV-2 and to test for (potential) individual immunity, 52",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "For sensitivity tested individual follow-up samples of SARS-CoV-2 PCR-confirmed individuals at different time 240 points and generated results.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}